Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting continued progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts. The company reported positive six-month results from its First-in-Human (FIH) study, supporting advancement to Group Two clinical surgeries.
Key highlights include a financing initiative launched to fund completion of the FIH study and accelerate commercialization activities. The next-generation accommodating intraocular lens (Ocumetics Lens) with a breakthrough technology design has been completed, incorporating significant advancements in manufacturability, surgical performance and scalability. Manufacturing of the redesigned Ocumetics Lens has commenced in Germany in preparation for planned Group Two surgeries, which remain on track for Q3 2026 in Mexico City.
All regulatory requirements necessary to proceed to Group Two surgeries have been successfully completed. Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities.
"The past several months have marked one of the most productive periods in Ocumetics' history," commented Dean Burns, President and Chief Executive Officer. "With group two surgeries expected to commence during the third quarter of 2026, we believe the Company is entering an important value-creation phase as we continue to build long-term shareholder value."
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, the company has launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities. Proceeds are expected to be used to complete Group Two FIH surgeries in Mexico City, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging activities, advance regulatory and quality assurance programs, and continue strategic partnership and commercialization initiatives.
Six-month follow-up data from Group One patients continue to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered to be legally blind that is now qualified to drive.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, representing years of research, engineering and product refinement. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production. Expected benefits include enhanced accommodative performance, simplified lens architecture with one-piece design, improved manufacturing consistency, elimination of internal interface materials (no air, water or oil), optimized surgical implantation characteristics, improved compatibility with the redesigned lens delivery system, and greater scalability for commercial manufacturing.
Manufacturing of the redesigned Ocumetics Lens has commenced with the company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of the planned Q3 2026 clinical surgeries.
Following the successful completion of Group One surgeries and encouraging six-month clinical results, Ocumetics continues preparations for Group Two FIH surgeries, which remain on schedule for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez and his experienced surgical team. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the company's updated lens delivery system.
Management believes positive one-month results of the Group Two patients will represent another meaningful value-creation milestone for Ocumetics as the company advances toward its larger clinical studies, future regulatory submissions and eventual commercialization.
